Charles River Laboratories International (CRL) Accounts Payables (2009 - 2025)

Charles River Laboratories International's Accounts Payables history runs 17 years deep, the most recent figure standing at $148.8 million for Q4 2025.

• In Q4 2025, Accounts Payables rose 6.03% year-over-year to $148.8 million; the TTM figure through Dec 2025 stood at $148.8 million (up 6.03% YoY), while the FY2025 annual figure was $148.8 million, up 6.03% from the prior year.
• Accounts Payables for Q4 2025 stood at $148.8 million, down from $169.6 million in the prior quarter.
• The five-year high for Accounts Payables was $226.0 million in Q1 2022, with the low at $110.9 million in Q2 2021.
• The 5-year median for Accounts Payables is $143.1 million (2024), against an average of $155.4 million.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables soared 90.56% in 2022, then slumped 46.9% in 2023.
• Charles River Laboratories International's Accounts Payables stood at $198.1 million in 2021, then climbed by 3.93% to $205.9 million in 2022, then slipped by 17.96% to $168.9 million in 2023, then slipped by 16.93% to $140.3 million in 2024, then advanced by 6.03% to $148.8 million in 2025.
• Business Quant data shows CRL's Accounts Payables at $148.8 million in Q4 2025, $169.6 million in Q3 2025, and $145.8 million in Q2 2025.